162 related articles for article (PubMed ID: 38295889)
1. The treatment of advanced melanoma: Current approaches and new challenges.
Boutros A; Croce E; Ferrari M; Gili R; Massaro G; Marconcini R; Arecco L; Tanda ET; Spagnolo F
Crit Rev Oncol Hematol; 2024 Apr; 196():104276. PubMed ID: 38295889
[TBL] [Abstract][Full Text] [Related]
2. Activity and safety of first-line treatments for advanced melanoma: A network meta-analysis.
Boutros A; Tanda ET; Croce E; Catalano F; Ceppi M; Bruzzone M; Cecchi F; Arecco L; Fraguglia M; Pronzato P; Genova C; Del Mastro L; Lambertini M; Spagnolo F
Eur J Cancer; 2023 Jul; 188():64-79. PubMed ID: 37196485
[TBL] [Abstract][Full Text] [Related]
3. Updates in the Management of Uveal Melanoma.
Barbi M; Carvajal RD; Devoe CE
Cancer J; 2024 Mar-Apr 01; 30(2):92-101. PubMed ID: 38527262
[TBL] [Abstract][Full Text] [Related]
4. Nivolumab plus ipilimumab in metastatic melanoma: a critical appraisal focused on specific subpopulations.
Vázquez-Montero L; de la Gala MDCÁ; de la Cruz-Merino L
Front Oncol; 2023; 13():1187840. PubMed ID: 37404764
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy of Human Melanoma: Past, Present, Future.
Mortezaee K; Majidpoor J
Curr Med Chem; 2024 Mar; ():. PubMed ID: 38454775
[TBL] [Abstract][Full Text] [Related]
6. The introduction of LAG-3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition.
Kreidieh FY; Tawbi HA
Ther Adv Med Oncol; 2023; 15():17588359231186027. PubMed ID: 37484526
[TBL] [Abstract][Full Text] [Related]
7. Determinants of overall survival in patients with metastatic uveal melanoma.
Demkowicz P; Pointdujour-Lim R; Miguez S; Lee Y; Jones BSCL; Barker CA; Bosenberg M; Abramson DH; Shoushtari AN; Kluger H; Francis JH; Sznol M; Bakhoum MF
Cancer; 2023 Oct; 129(20):3275-3286. PubMed ID: 37382208
[TBL] [Abstract][Full Text] [Related]
8. Systemic Therapy of Metastatic Melanoma: On the Road to Cure.
Steininger J; Gellrich FF; Schulz A; Westphal D; Beissert S; Meier F
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33804800
[TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy and safety of immune checkpoint inhibitors for unresectable advanced melanoma: A systematic review and network meta-analysis.
Li Y; Liang X; Li H; Chen X
Int Immunopharmacol; 2023 Feb; 115():109657. PubMed ID: 36608446
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of resistance to immune checkpoint inhibitors in melanoma: What we have to overcome?
Ziogas DC; Theocharopoulos C; Koutouratsas T; Haanen J; Gogas H
Cancer Treat Rev; 2023 Feb; 113():102499. PubMed ID: 36542945
[TBL] [Abstract][Full Text] [Related]
11. Double Trouble: Immunotherapy Doublets in Melanoma-Approved and Novel Combinations to Optimize Treatment in Advanced Melanoma.
Dimitriou F; Hauschild A; Mehnert JM; Long GV
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-22. PubMed ID: 35658500
[TBL] [Abstract][Full Text] [Related]
12. Frontline BRAF Testing-Guided Treatment for Advanced Melanoma in the Era of Immunotherapies: A Cost-Utility Analysis Based on Long-term Survival Data.
Wu B; Shi L
JAMA Dermatol; 2020 Nov; 156(11):1177-1184. PubMed ID: 32697281
[TBL] [Abstract][Full Text] [Related]
13. Nivolumab/Relatlimab: A Novel Addition to Immune Checkpoint Inhibitor Therapy in Unresectable or Metastatic Melanoma.
Phillips AL; Reeves DJ
Ann Pharmacother; 2023 Jun; 57(6):738-745. PubMed ID: 36268952
[TBL] [Abstract][Full Text] [Related]
14. Outcomes after progression of disease with anti-PD-1/PD-L1 therapy for patients with advanced melanoma.
Patrinely JR; Baker LX; Davis EJ; Song H; Ye F; Johnson DB
Cancer; 2020 Aug; 126(15):3448-3455. PubMed ID: 32463489
[TBL] [Abstract][Full Text] [Related]
15. Immune checkpoint inhibitors as first line in advanced melanoma: Evaluating progression-free survival based on reconstructed individual patient data.
Ossato A; Damuzzo V; Baldo P; Mengato D; Chiumente M; Messori A
Cancer Med; 2023 Feb; 12(3):2155-2165. PubMed ID: 35920297
[TBL] [Abstract][Full Text] [Related]
16. The concepts of rechallenge and retreatment with immune checkpoint blockade in melanoma patients.
Zaremba A; Eggermont AMM; Robert C; Dummer R; Ugurel S; Livingstone E; Ascierto PA; Long GV; Schadendorf D; Zimmer L
Eur J Cancer; 2021 Sep; 155():268-280. PubMed ID: 34392069
[TBL] [Abstract][Full Text] [Related]
17. Evolving Management of Stage IV Melanoma.
Switzer B; Piperno-Neumann S; Lyon J; Buchbinder E; Puzanov I
Am Soc Clin Oncol Educ Book; 2023 Jan; 43():e397478. PubMed ID: 37141553
[TBL] [Abstract][Full Text] [Related]
18. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
19. Association Between Sex and Immune Checkpoint Inhibitor Outcomes for Patients With Melanoma.
Jang SR; Nikita N; Banks J; Keith SW; Johnson JM; Wilson M; Lu-Yao G
JAMA Netw Open; 2021 Dec; 4(12):e2136823. PubMed ID: 34854905
[TBL] [Abstract][Full Text] [Related]
20. MAPKinase inhibition after failure of immune checkpoint blockade in patients with advanced melanoma - An evaluation of the multicenter prospective skin cancer registry ADOREG.
Kreft S; Glutsch V; Zaremba A; Schummer P; Mohr P; Grimmelmann I; Gutzmer R; Meier F; Pföhler C; Sachse MM; Meiss F; Forschner A; Haferkamp S; Welzel J; Terheyden P; Herbst R; Utikal J; Kaatz M; Weishaupt C; Kreuter A; Debus D; Duecker P; Sindrilaru A; Löffler H; Schley G; Weichenthal M; Schadendorf D; Ugurel S; Gesierich A; Schilling B
Eur J Cancer; 2022 May; 167():32-41. PubMed ID: 35366571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]